Risk of adverse events with fibrates
- PMID: 15464682
- DOI: 10.1016/j.amjcard.2004.06.033
Risk of adverse events with fibrates
Abstract
An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis. This difference was especially noticeable in patients taking the combination of gemfibrozil and a statin, particularly cerivastatin.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical